fda.gov — [04-22-2011] The U.S. Food and Drug Administration (FDA) continues to evaluate the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection, associated with use of Tysabri (natalizumab) for the treatment of multiple sclerosis (MS) and Crohn's disease.
May 24, 2011 View in Crawl 4
No comments yet
It's quiet in here... can you hear the echo?